Plus Therapeutics (PSTV) received notice of an advance payment of $1.6M from the Cancer Prevention and Research Institute of Texas as part of the Company’s previously awarded $17.6M grant. The funding supports and accelerates the Company’s clinical development of REYOBIQ for the ReSPECT-LM dose optimization trial and further develops the Company’s CNSide LM diagnostic test as a key pivotal trial endpoint.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PSTV:
- Plus Therapeutics Advances Pediatric Brain Tumor Treatment with New Clinical Study
- Plus Therapeutics announces initial patients treated in ReSPECT-LM trial
- Plus Therapeutics reaches FDA agreement to initiate ReSPECT-LM trial
- Plus Therapeutics provides business update on CNSide Diagnostics subsidiary
- 3 Penny Stocks to Watch Now, 6/26/25